Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-11-22 10:25 CET (UTC+1h)
 
Pandu
Regular

India,
2017-10-23 06:23

Posting: # 17904
Views: 329
 

 PK Stat analysis for Levothyroxine sodium studies for USFDA submission [Design Issues]

Hi,
We are conducting Levothyroxine sodium studies for USFDA submission, I required one clarity as per OGD.

OGD says that Post-dose levothyroxine measurements by the baseline levothyroxine value should be corrected in each period for each subject. The baseline value should be obtained from the average of three levothyroxine measurements taken before dosing (i.e., at 0.5 h, 0.25 h, and 0 h pre-dose.

OGD is not mentioned about exclusion of subjects from Pharmacokinetic and statistical analysis, after baseline correction if subject having more-than 5% of Cmax on pre-dose concentration. This criteria we can apply for endogenous products or not?

Awaiting for your replays.
jag009
Hero

NJ,
2017-10-24 05:45

@ Pandu
Posting: # 17909
Views: 234
 

 PK Stat analysis for Levothyroxine sodium studies for USFDA submission

Hi,

» OGD is not mentioned about exclusion of subjects from Pharmacokinetic and statistical analysis, after baseline correction if subject having more-than 5% of Cmax on pre-dose concentration. This criteria we can apply for endogenous products or not?

Why now? Theoretically speaking after baseline correction the amount of drug in the system is "ought" to be attributed to the drug products.

J
Back to the forum Activity
 Thread view
Bioequivalence and Bioavailability Forum | Admin contact
17,494 Posts in 3,746 Threads, 1,086 registered users;
34 users online (0 registered, 34 guests).

The whole purpose of education is
to turn mirrors into windows.    Sydney J. Harris

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed